عرض بسيط للتسجيلة

المؤلفAhmed, Zaqout
المؤلفAlmaslamani, Muna A.
المؤلفChemaitelly, Hiam
المؤلفHashim, Samar A.
المؤلفIttaman, Ajithkumar
المؤلفAlimam, Abeir
المؤلفRustom, Fatma
المؤلفDaghfal, Joanne
المؤلفAbukhattab, Mohammed
المؤلفAlMukdad, Sawsan
المؤلفKaleeckal, Anvar Hassan
المؤلفLatif, Ali Nizar
المؤلفButt, Adeel A.
المؤلفBertollini, Roberto
المؤلفAl-Khal, Abdullatif
المؤلفOmrani, Ali S.
المؤلفAbu-Raddad, Laith J.
تاريخ الإتاحة2023-07-11T08:24:47Z
تاريخ النشر2022-11
اسم المنشورInternational Journal of Infectious Diseases
المعرّفhttp://dx.doi.org/10.1016/j.ijid.2022.09.023
الاقتباسZaqout, A., Almaslamani, M. A., Chemaitelly, H., Hashim, S. A., Ittaman, A., Alimam, A., ... & Abu-Raddad, L. J. (2022). Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. International Journal of Infectious Diseases, 124, 96-103.
الرقم المعياري الدولي للكتاب1201-9712
معرّف المصادر الموحدhttps://www.sciencedirect.com/science/article/pii/S1201971222005227
معرّف المصادر الموحدhttp://hdl.handle.net/10576/45351
الملخصObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe conducted a matched case-control study among all individuals eligible for sotrovimab treatment per United States Food and Drug Administration guidelines in the resident population of Qatar. The odds of progression to severe forms of COVID-19 were compared in cases (treatment group) versus controls (eligible patients who opted not to receive the treatment). Subgroup analyses were conducted. ResultsA total of 3364 individuals were eligible for sotrovimab treatment during the study period, of whom 519 individuals received the treatment, whereas the remaining 2845 constituted the controls. The adjusted odds ratio of disease progression to severe, critical, or fatal COVID-19 comparing the treatment group to the control group was 2.67 (95% confidence interval 0.60-11.91). In the analysis including only the subgroup of patients at higher risk of severe forms of COVID-19, the adjusted odds ratio was 0.65 (95% confidence interval 0.17-2.48). ConclusionThere was no evidence for a protective effect of sotrovimab in reducing COVID-19 severity in a setting dominated by the BA.2 subvariant.
اللغةen
الناشرElsevier
الموضوعCOVID-19
SARS-CoV-2
Sotrovimab
Omicron
BA.2
Epidemiology
العنوانEffectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
النوعArticle
الصفحات96-103
رقم المجلد124
Open Access user License http://creativecommons.org/licenses/by/4.0/
ESSN1878-3511
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة